The infrastructure of drug development has changed dramatically. No longer are new developments dominated by big pharmaceutical companies, as universities and biotechnology firms are taking drugs forward. However, the management of early studies has become more challenging as many tasks must be outsourced to specialists and virtual teams must be established. Keith Williams at Boyd Consultants offers a wider perspective from his research on the history of the pharmaceutical industry and its evolution over the last 200 years or more.